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The Syntaxin-1A gene single nucleotide
polymorphism rs4717806 associates with the risk
of ischemic heart disease
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Abstract
Ischemic heart disease (IHD) has a genetic predisposition and a number of cardiovascular risk factors are known to be affected by
genetic factors. Development of metabolic syndrome and insulin resistance, strongly influenced by lifestyle and environmental
factors, frequently occur in subjects with a genetic susceptibility. The definition of genetic factors influencing disease susceptibility
would allow to identify individuals at higher risk and thus needing to be closely monitored.
To this end, we focused on a complex of soluble-N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs),
playing an important role in metabolic syndrome and insulin resistance, involved in endothelial dysfunction and heart disease. We
assessed if genetic variants of the SNARE genes are associated with IHD.
SNAP25 rs363050, Stx-1A rs4717806, rs2293489, and VAMP2 26bp ins/del genetic polymorphisms were analyzed in a cohort of
100 participants who underwent heart surgery; 56 of themwere affected by IHD, while 44were not. A statistical association of plasma
glycemia and insulin resistance, calculated as Triglyceride glucose (TyG) index, was observed in IHD (P< .001 and P= .03,
respectively) after binomial logistic stepwise regression analysis, adjusted by age, gender, diabetes positivity, waist circumference,
and cholesterol plasma level. Among genetic polymorphisms, rs4717806(A) and rs2293489(T), as well as the rs4717806 –
rs2293489 (A-T) haplotype were associated with higher risk for IHD (Pc= .02; Pc= .02; P= .04, respectively). Finally, a statistical
association of rs4717806(AA) genotype with higher TyG index in IHD patients (P= .03) was highlighted bymultiple regression analysis
considering log-transformed biochemical parameters as dependent variable and presence of coronary artery disease, age, gender,
waist circumference, presence of diabetes as predictors. These results point to a role of the Stx-1A rs4717806 SNP in IHD, possibly
due to its influence on Stx-1A expression and, as a consequence, on insulin secretion and glucose metabolism.
Abbreviations: CABG = coronary artery by-pass grafting, CG = control group, GWAS =GenomeWide Association study, HWE
=Hardy-Weinberg equilibrium, IHD= ischemic heart disease, PCR= polymerase chain reaction, SNAP25= synaptosomal protein of
25 kDa, SNAREs = soluble-N-ethylmaleimide-sensitive factor attachment protein receptors, SNP = single nucleotide polymorphism,
Stx-1A = syntaxin 1A, T2DM = type 2 diabetes mellitus, TyG = Trigyceride-glucose.
Keywords: coronary artery disease, ischemic heart disease, Syntaxin-1A, insulin resistance
1. Introduction
Ischemic heart disease (IHD), characterized by atherosclerotic
coronary artery lesions, has a well-known genetic predisposition
and tends to cluster in families.[1] A number of cardiovascular
risk factors that recognize a familiar aggregation have been
identified; these include serum cholesterol, blood pressure levels,
diabetes, and obesity.[2] Environmental influence such as air
pollution, as well as modifiable lifestyle habits, including diet, low
levels of physical activity and smoke, also contribute to the
modulation of IHD risk.[3] The occurrence of IHD, nevertheless,
cannot be explained by the variation of the traditional
cardiovascular risk influences alone, and the development of
risk charts based on them would misclassify a high proportion of
cases, suggesting that other, still unknown, genetic elements play
an important role in this condition.[4] The role of genetics in the
etiology of coronary artery disease is only partially understood
and there is a great need to clarify the genetic basis of
susceptibility to IHD, in order to identify cases with a true
heritable component of this condition.
Epidemiological studies indicate that IHD is associated with
the metabolic syndrome,[5–7] defined as a cluster of glucose
intolerance, hypertension, dyslipidemia, and central obesity. In
particular, a low response to insulin action in adipose tissue,
skeletal muscle, and liver, resulting in insulin resistance, is known
as the headstream of metabolic syndrome.
A recent study highlighted the central role played by a complex
of soluble-N-ethylmaleimide-sensitive factor attachment protein
receptors (SNAREs) in metabolic diseases,[8,9] which are also
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involved in the pathogenesis of type 2 diabetes mellitus
(T2DM)[10] as well as in cardiac functions.[11–13] The SNARE-
complex includes the two t-SNARE proteins, synaptosomal
protein of 25kDa (SNAP25) and syntaxin 1A (Stx-1A), as well as
the v-SNARE protein VAMP2. To allow exocytosis the amino
terminal of SNAP25 binds to Stx-1A and the carboxy-terminal
binds to VAMP2, forming the four-helical bundle that brings
secretory granules in close contact with the plasma membrane,
thus enabling fusion to occur.
Stx-1A protein, in particular, is widely expressed in the brain,
in the endocrine system and in the heart.[14] This protein was
shown to regulate signaling pathways in myocardial ischemic
reperfusion injury, such as KATP channels and calcium
channels.[14–17] Notably, Stx-1A undergoes up-regulation as a
consequence of ischemia,[18] suggesting a potential role of Stx-1A
in cardiac injury.
Two specific singular nucleotide polymorphisms (SNP),
namely rs4717806 and rs2293489, located, respectively in
Stx-1A- locus in intron 9 and in WBSCR22 gene, upstream to
50UTR, are suspected to be involved in protein expression.[19,20]
SNAP25, on the other hand, is known to modulate several
processes besides the actual fusion event, including the activity of
potassium voltage gated (Kv) 2.1 channels.[21] A specific SNP
rs363050 located into intron 1 of the SNAP25 gene has been
associated with SNAP25 protein expression.[22] Finally, a
VAMP2 gene deletion of 16bp located at 2kb from 30 flanking
regions of human VAMP2, in an intergenic region[23] was
associated with neurologic disease,[24] and is suspected to impair
SNARE functionality, indicating the need to investigate this
deletion, as well as mechanisms involving SNARE activity.
We evaluated the association of the over described genetic non
coding variants of the SNARE complex genes, suggested to be
involved in protein expression,[19,20,22,23] with IHD to ascertain a
possible involvement of the SNARE complex in the risk to
develop IHD. We also defined possible correlations between
genetic SNARE polymorphism and biological pattern at risk for
IHD. To this end, the distribution of SNAP25 rs363050, Stx-1A
rs4717806, rs2293489, and VAMP2 26bp ins/del genetic
polymorphisms were analyzed in a clinically and biochemically
characterized cohort of patients who had recently undergone
heart surgery.
2. Materials and methods
2.1. Patients
We prospectively and consecutively enrolled 100 adult patients
(61 males and 39 females, all Caucasians), aged>18 years (mean
age=71 years; SD=10.7), admitted as in-patients to the
Cardiology Rehabilitation Department of the Don Carlo
Gnocchi Foundation (Milan), after undergoing elective heart
surgery.
Heart surgery interventions included coronary artery by-pass
grafting (CABG), valve replacement or repair and/or ascending
aorta surgery. Patients after heart transplant or left ventricular
assist device implant were excluded. The study has been
conducted in accordance with the declaration of Helsinki and
the research protocol was approved by the Ethical Committee of
the Don Carlo Gnocchi Foundation (protocol number: 16/2015/
CE_FdG/SA). Informed consent to participate in the study has
been signed by all participants.
Venous blood sample was collected at the beginning of the
rehabilitation period, at admission in the Cardiology Rehabilita-
tion Department (mean time of 10.8±5.7 days after surgery). Red
and white blood cells were counted by Sysmex XE-2100 (Dasit;
Milan, Italy). Biochemical parameters were measured by UniCel
DxC 800 Synchron (Beckman Coulter; Brea, California). They
included Creatinine, Sodium and Potassium, C-Reactive Protein,
Total Proteins, Alanine Aminotransferase, Aspartate Aminotrans-
ferase, Creatin-kinase, Total Cholesterol, Cholesterol HDL,
Cholesterol LDL, Triglycerides, Troponin, Ferritin, Transferrin
and Fasting Glucose. The TyG index was calculated as TyG= ln
[Fasting triglyceride (mg/dl) x Fasting glucose (mg/dl)] / 2).[25]
Patients were divided in 2 groups: those affected by known IHD
(56 subjects) and those who were not affected by coronary artery
disease (44 patients)(control group -CG-) (Table 1).
Patients were classified as affected by IHD if admitted after
coronary artery by-pass graft (CABG, alone or combined to valve
replacement) or after valve replacement (or valvuloplasty), but
with a well-documented history of coronary artery disease, such
as previous myocardial infarction or clear atherosclerotic
coronary lesions demonstrated at coronary angiography. All
the other patients were classified as CG. Both demographic and
clinical baseline data are reported in Table 1.
Table 1
General demographic, anthropometric, and clinical characteristics of individuals with a diagnosis of ischemic heart disease (IHD) and of
individuals in the control group (CG).
ALL (n=100) IHD (n=56) CG (n=44) P
Sex (M/F) 61/39 40/16 21/23 .03
∗
Age (yrs) 73.0±11.0 73.0±13.0 73.5±11.0 .97
Hypertension 69 42 27 .12
Height (cm) 167±11 169±12.0 165±9.5 .07
BMI (kg/m2) 24.6±4.9 25.5±4.5 24.1±5.7 .08
Waist circumference (cm) 96.0±18.0 100.0±16.0
∗
93.5±17.0
∗
.03
∗
WHtR (cm/m) 58.07±7.0 58.90±6.7 57.02±7.2 .11
Time from Surgery (days) 9.0±5.0 10.0±6.0 7.5±4.0 .10
Comorbidities 117 71 46 .26
Diabetes 23 19
∗
4
∗
.005
∗
Number of comorbidities per patient 1.18±0.97 1.27±1.02 1.05±0.91 .26
Patients without comorbidities (%) 28±28 15±26.8 13±29.5 .92
Left ventricular Ejection Fraction (%) 56.0±10.0 55.0±12.0 58.0±10.0 .31
Demographic and anthropometric indexes. Values expressed as median± Interquartile range (IQR); P value was calculated by Mann–Whitney. For categorical variables: P after Fisher test.
∗
Statistically significant P values, WHtR=waist / height ratio.
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2.2. SNARE genotyping
Genomic DNA was isolated from peripheral blood mononuclear
cells by phenol-chloroform extraction.
Stx-1A and SNAP25 SNPs were genotyped using the Taqman
SNP Genotyping Assays (Applied Biosystems by Life Technolo-
gies, Foster City, CA, USA) on an ABI PRISM 7000 Sequence
Detection System. Human Pre-Designed Assays (Applied Bio-
systems by Life Technologies) were used for SNAP25 rs363050
SNP C_329097_10, Stx-1A rs4717806 SNP located in intron 9:
C__27872627_10, Stx-1A rs2293489 located in WBSCR22
gene, upstream to 50UTR Stx-1A gene: C__15971044_10.
The VAMP2 gene 26bp Ins/Del polymorphism was genotyped
by polymerase chain reaction (PCR). PCR was performed with a
GeneAmp PCR System 9700 (Applied Biosystems), using
VAMP2 F-50-ACAAAGTGCGCCTTATACGC-30 and VAMP2
R-50-GATTTTCCTTGACGACACTC-30 primers as described in
Falbo et al.[23] Amplicons (10mL) were detected by electropho-
resis on a 3% agarose gel.
2.3. Statistical analysis
The distribution of biochemical, demographic and clinical
parameters was evaluated by Kolmogorov-Smirnov test to assess
possible deviations from the Gaussian model. Since the large
majority of parameters had a non-normal distribution, the non
parametric Mann–Whitney test was adopted to compare the
parameters distribution in the groups of IHD vs CG patients.
Binomial logistic regression (forward stepwise analysis) was
adopted to evaluate specific biomarkers of IHD risk adjusted for
possible bias due to gender, diabetes and circumference waist.
Pearson’s chi-square test was performed to compare the
distribution of categorical variables in the 2 studied groups as
well as to exclude any deviation of SNPs genotype distribution
from Hardy–Weinberg equilibrium (HWE). For genotype
analyses, chi-square statistics were calculated with 2 degrees of
freedom (referred to the three different genotypes). Singular allele
frequency association, haplotype analysis distribution and gene
interaction score were calculated by SHEsis software
http://shesisplus.bio-x.cn/SHEsis.html.[26,27] This analysis
allowed to evaluate the association of singular allele on each
chromosome giving also information about possible linkage
disequilibrium between different alleles. P-values were corrected
using the Benjamini–Hochberg approach to False Discovery
Rate, as provided by SHEsis software.[28]
Finally, multiple regression analysis was adopted to evaluate
the putative association of biochemical parameters (suitably
transformed) with Stx-1A genotypes and IHD risk factors.
3. Results
3.1. Anthropometric and Biochemical characterization of
IHD and CG patients
Demographic, anthropometric and clinical variables are reported
in Table 1. A higher prevalence of men was reported in IHD
(71.4%) than in CG patients (47.7%, P= .03). Median waist
circumference was higher in IHD than in CG patients (P= .05).
(T2DM) was diagnosed in 23 patients, nineteen of them being
IHD patients (P= .005).
Biochemical parameters and Insulin resistance, obtained by
calculating the Triglyceride-glucose (TyG) index for each
patient[25] are reported in Table 2. Differences in distributions
of White blood cell (WBC) count, Creatinin (Crea), AST,
Tropinin and Ferritin levels as well as glucose plasma level, lipidic
pattern (total cholesterol, LDL and HDL fractions) and TyG
Table 2
Biochemical parameters distribution in individuals with a diagnosis of ischemic heart disease (IHD) and in individuals in the control group
(CG).
ALL (n=100) IHD (n=56) CG (n=44) P
Hb (g/dL) 10.6±1.7 10.5±2.0 11.1±1.8 .61
RBC (n/mL
∗
106) 3.7±0.7 3.7±0.6 3.8±0.6 .30
Ht (%) 32.5±5.1 31.9±5.4 31.5±4.8 .56
WBC (n/mL
∗
103) 8.9±3.4 9.5±3.2 7.7±4.0 .04
∗
Lymphocytes (%) 22.4±8.6 20.6±8.6 22.5±6.9 .55
Creatinine (mg/dL) 0.8±0.3 1.0±0.3
∗
0.8±0.3
∗
.001
∗
e-GFR (mL/min/1.73 cm2) 77.4±26.0 79.2±27.0 77.1±21.0 .31
Na+ (mEq/L) 139.0±3.0 139.0±4.0 139.0±3.0 .24
K+ (mEq/L) 4.4±0.4 4.5±0.4 4.4±0.4 .05
c-RP (mg/dL) 4.3±5.4 2.6±5.8 4.6±4.5 .19
Total plasma Protein (g/dL) 5.7±0.8 5.7±0.7 5.9±0.9 .78
AST (IU/L) 19.5±16.0 18.0±13.0
∗
22.0±18.0
∗
.04
ALT (IU/L) 30.0±19.0 29.0±19.0 32.0±24.0 .15
CK (IU/L) 38.5±29.0 41.0±37.0 38.0±23.0 .82
Troponin (ng/L) 0.08±0.10 0.06±0.07
∗
0.11±0.13
∗
.004
∗
Ferritin (ng/mL) 237.3±262.3 200.6±202.4
∗
333.4±252.4
∗
.04
∗
Transferrin (mg/dL) 195.0±43.0 204.0±48.0 188.0±38.0 .06
Fasting Glucose (mg/dL) 96.0±27.0 102.0±25.0
∗
86.0±18.0
∗
.002
∗
Total Cholesterol (mg/dL) 135.5±53.0 121.0±29.0
∗
157.0±58.0
∗
.01
∗
HDL Cholesterol (mg/dL) 31.5±13.0 30.0±12.0
∗
34.0±15.0
∗
.04
∗
LDL Cholesterol (mg/dL) 78.0±37.0 74.0±18.0
∗
99.0±39.0
∗
.004
∗
Triglycerides (mg/dL) 106.0±44.0 102.0±47.0 107.0±45.0 .78
TyG index 4.6±0.4 4.7±0.4
∗
4.5±0.3
∗
.016
∗
Biochemical parameter values expressed as median± Interquartile range (IQR): P value was calculated by Mann–Whitney. TyG Index= the product of fasting glucose and triglycerides levels.
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index were observed when IHD and CG patients were compared.
Binomial logistic forward stepwise regression analysis was used
to analyze the possible association of biochemical parameters
with different phenotypes of cardiovascular disease (as dependent
variable, IHD vs CG) after adjustment for all the other
biochemical parameters and for age, gender, diabetes status,
and waist circumference.
A higher fasting glucose level (median± Interquartile range
mg/dL) (102.0±25.0 vs 86.0±18.0; P= .002) as well as a higher
TyG index (4.7±0.4 vs 4.5±0.3; P= .016) were observed in IHD
patients compared to controls. These differences retained
statistical significance also after imputing as covariate parame-
ters: age, gender, diabetes positivity, waist circumference and
cholesterol plasma level (P= .03).
3.2. Genetic characterization of IHD and CG patients:
SNAP25, Stx-1A, VAMP2
All patients were genetically characterized for SNAP25, Stx-1A,
and VAMP2 polymorphisms; the genotype distribution resulted
in Hardy–Weinberg equilibrium both in the IHD and the CG
group. Genetic profiles were then evaluated in both IHD and CG
patients. Genotype distribution for SNAP25, Stx-1A, and
VAMP2 polymorphisms is reported in Table 3; no genotype
association with IHD was observed. However, the comparison
done by regression analysis, performed with Shesis software,
adjusting for age, gender, diabetes status, waist circumference,
total cholesterol, LDL, and HDL fractions as covariates,
highlighted a significant association of Stx-1A rs4717806(A)
and rs2293489(T) minor alleles with IHD risk (Pc= .02; OR:
2.43, 95%CI:1.1–5.3 and, Pc= .02; OR: 2.86, 95%CI:1.3–6.4,
respectively) (Table 4) No association was found with the major
allele. No statistical skewing was observed as to any other
polymorphism analyzed.
Haplotype analysis evidenced a linkage disequilibrium of
rs4717806 and rs2293489 polymorphisms (r2= .95) as well as a
significant gene-gene interaction (P= .04) and a specific haplo-
type association with ischemic risk. Thus, the rs4717806 –
rs2293489 (A-T) haplotype was more frequent in IHD (34.8%)
than in CG patients (21.5%) (Pc= .04; OR:1.94, 95%CI: 1.1–
3.7); this result was corroborated by the observation that the
complementary haplotype rs4717806–rs2293489 (T-C) showed
a protective effect (Pc= .06 OR:0.53, 95%CI:0.3–1.0) (Table 5).
3.3. SNAP25, Stx-1A, VAMP2 polymorphisms association
with biochemical parameters
The putative association of SNAP25, Stx-1A, VAMP2 genetic
variantswithall biochemical parameters in IHDandCGwas tested
by multiple regression analyses, considering log-transformed
Table 3
SNAP25 rs36305, Stx-1A rs4717806, and rs2293489, VAMP2 26bp ins/del genotypic and allelic polymorphism distribution in patients with
ischemic heart disease (IHD) and in the control group (CG).
IHD (n=56) CG (n=44) Pc value
N % N %
SNAP25 Rs363050
AA 20 35.7 16 36.4
AG 23 41.1 17 38.6
GG 13 23.2 11 25.0
.96
A 63 56.2 49 55.7
G 49 43.8 39 44.3
.94
Stx-1A rs4717806
TT 25 44.6 26 59.1
AT 23 41.1 16 36.4
AA 8 14.3 2 4.5
.17
T 73 65.2 68 77.3
A 39 34.8 20 22.7
.08
Stx-1A rs2293489
CC 25 44.6 26 51
CT 22 39.3 17 38.6
TT 9 16.1 1 2.3
.06
T 40 35.7 19 21.6
C 72 64.3 69 78.4
.05
VAMP2 26bp Ins/Del
Ins/Ins 41 73.2 35 79.5
Ins/Del 15 26.8 9 20.5
.61
Ins 97 86.6 79 89.8
Del 15 13.4 9 10.2
.32
N: absolute number of subjects, Pc=P value corrected for degree of freedom.
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biochemical parameters as dependent variable and presence of
coronary artery disease, age, gender, waist circumference,
presence of diabetes as predictors. The logarithmic transformation
allowed to reduce the degree of skewness of the distribution of
biochemical parameters.
Results showed that the Stx-1A rs4717806(TT) genotype was
associated with a protective effect on both Triglyceride levels and
TyG index compared to the (AA) genotype (b=0.29, SE=0.15,
P= .05) and (b=0.05, SE=0.02, P= .01), respectively. This
genotype was associated with the TyG Index alone in the
subsample of IHD patients (b=0.04, SE=0.02, P= .036)
(Fig. 1). No significant association did emerge as to Stx-1A
rs2293489 polymorphism. No other association emerged in any
of the other parameters evaluated.
4. Discussion
The primary finding of this study is the characterization of a
significant association between the Stx-1A polymorphisms
rs4717806(A) and the rs2293489(T) alleles and IHD develop-
ment, both as single minor alleles, and as haplotype. Moreover,
the correlation analysis of SNARE genetic polymorphism with
metabolic biochemical risk factors for IHD evidenced the
presence of a significant higher level of TyG index in IHD
patients carrying the Stx-1A rs4717806(A), but not the Stx-1A
rs2293489(T) allele, after adjustment for possible confounding
factors. This observation suggests that rs4717806(A) involve-
ment in IHD is stronger than involvement of Stx-1A rs2293489
(T) allele, whose association with IHD may be due to a linkage
disequilibrium with rs4717806(A). It is noteworthy that STX1A
rs4717806 (AA) genotype was associated with a lower protein
expression with a tendency for gene dose effect.[19]
TyG index is a useful surrogate marker for insulin resis-
tance,[25] which is independently associated with the presence of
coronary artery atherosclerosis;[29] notably, this parameter was
recently shown to be an important risk factor for IHD.[30,31]
Insulin resistance leads to a relative reduction of insulin action,
then to hyperglycemia and consequently to higher production of
insulin by pancreatic b-cells.
Insulin exocytosis depends on the intracellular storing of
insulin within vesicles, vesicle trafficking and fusion to the
membrane of pancreatic b-cells.[32,33] SNARE proteins constitute
the ‘core complex’ that regulates vesicle trafficking and fusion in
b–cells.[34] Within these proteins, Stx-1A has been shown to bind
and regulate calcium channels and voltage gated Kþ channels of
the pancreatic b–cell.[35,36] Recently, in transgenic mice for Stx-
1A, it was demonstrated that subtle fluctuations in the expression
of this protein determine changes in insulin secretion, ultimately
resulting in glucose intolerance.[37] The Stx-1A gene has been
mapped to chromosome 7q11. A quantitative trait locus for
fasting glucose has been found linked to 7q in Europeans,[38] thus
adding confirmatory evidence that this region may contain gene
or genes with an important impact on insulin and glucose
metabolism regulation.[39]
Evidence here reported leads to assume a putative role of Stx-
1A rs4717806 in IHD, possibly due to its influence in insulin-
dependent glucose metabolism and therefore also in altered lipids
pathways, which are well-known risk factors for cardiovascular
Table 5
Stx-1A rs4717806 and rs2293489 haplotype analysis of distribution in ischemic heart disease (IHD) and Control group (CG) performed by
Shesis plus software.
SNPs Haplotype IHD (n=56) CG (n=44) Pc OR 95% CI
Stx-1A
rs4717806- rs2293489
A-T 39 34.8 19 21.5 .04 1.94 1.1–3,7
T-C 72 64.2 68 77.2 .06 0.53 0.3–1.0
Pc=P value corrected using False Discovery Rate, CI = confidence interval, OR = odds ratio.
Table 4
SNAP25 rs36305, Stx-1A rs4717806, and rs2293489, VAMP2 26bp
ins/del, Minor allele effect of association with ischemic heart
disease (IHD) vs Control group (CG), calculated by regression
analysis model with Shesis software.
SNPs Minor allele Pc OR 95% CI
SNAP25 Rs363050 G .49 0.80 0.4–1.5
Stx-1A rs4717806 A .02 2.43 1.1–5.3
Stx-1A rs2293489 T .02 2.86 1.3–6.4
VAMP2 26bp ins/del Del .75 1.19 0.4–3.7
Age, gender, positivity for diabetes, total Cholesterol, as well as LDL and HDL fractions were
considered as covariates.
Pc=P value corrected using False Discovery Rate. CI = confidence interval, OR = odds ratio.
Figure 1. Triglyceride-glucose (TyG) index distribution in relationship with Stx-
1A rs4717806 genotype in 56 patients affected by ischemic heart disease (IHD)
(grey boxes) and in 44 subjects of control group (CG) (white boxes). Outline
values are represented by code number.
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disease.[40]We cannot nevertheless exclude that the correlation of
Stx-1A with IHD is the effect of a lower efficacy of KATP channel,
resulting in higher risk for atherosclerosis.[11]
So far Stx-1A protein has been reported also to be able to
regulate myocardial injury-related signaling pathways such as
KATP channels and calcium channels.
[14,15] Increased Stx-1A
expression has been suggested to participate in cell salvage or
repair, as a consequence of its ability to mediate neurotransmitter
release and plasma membrane recycling, thereby exerting protec-
tion.[18] A lower expression of this protein, thus, could reduce
hypoxia/reoxygenation-induced cardiomyocyte apoptosis and cell
viability, resulting in a reduced degree of cardioprotection.[12]
Notably, even if our results will need to be replicated in larger
cohorts of IHD patients, they are consistent with evidence
reported by an important Genome-Wide Association study
(GWAS), which showed a strong association of 7q11 region with
Triglyceride alterations.[41]Stx-1Amaps in a region 70kb close to
one of the genes suggested by GWAS: that is MLX-interacting
protein-like (MLXIPL), significantly associated with Coronary
heart disease.[42] An in-depth evaluation of the Stx-1A SNPs
influence in cardiologic risk is warranted to confirm the
involvement of these SNPs in IHD.
5. Conclusions
Our results suggest a role of Stx-1A rs4717806 SNP in IHD,
possibly due to its influence in Stx-1A expression and, at cascade,
to insulin secretion and to glucose dependent metabolism.
This study may be considered a preliminary investigation; if
confirmed by further studies, these results could help in
identifying those individuals in whom strong efforts to prevent
metabolic disorders and reduce cardiological risk is needed.
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